Publication Name	World Journal of Gastroenterology
Manuscript ID	52516
Country	Japan

Received	2019-12-30 18:51
Peer-Review Started	2019-12-30 18:52
To Make the First Decision
Return for Revision	2020-02-29 22:27
Revised	2020-03-05 15:34
Second Decision	2020-04-03 12:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2020-04-04 02:53
Articles in Press	2020-04-04 02:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-04-20 01:48
Publish the Manuscript Online	2020-04-21 06:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Minireviews
Article Title	Update on quinolone-containing rescue therapies for Helicobacter pylori infection
Manuscript Source	Invited Manuscript
All Author List	Hideki Mori and Hidekazu Suzuki
ORCID	Author(s) ORCID Number Hideki Mori http://orcid.org/0000-0001-8830-4671 Hidekazu Suzuki http://orcid.org/0000-0002-8994-6163
Funding Agency and Grant Number
Corresponding Author	Hideki Mori, MD, PhD, Doctor, Doctor, Postdoctoral Fellow, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, University of Leuven, Herestraat 49 Box 701, Leuven 3000, Belgium. hideki.mori@kuleuven.be
Key Words	Helicobacter pylori; Levofloxacin; Sitafloxacin; Moxifloxacin; gyrA; Vonoprazan
Core Tip	The efficacies of 7-d levofloxacin or moxifloxacin, -containing regimens are becoming less effective in recent years due to the increasing antibiotic resistance, which necessitates 10-d or 14-d regimens or bismuth containing regimen are needed to achieve sufficient eradication rates. gyrA mutation is the most sensitive marker for predicting successful eradication in using quinolone-containing therapies. Thus, analysis of gyrA mutation before treatments is recommended. Seven-day sitafloxacin-amoxicillin-vonoprazan triple therapy is the best choice for third-line treatment at present.
Publish Date	2020-04-21 06:56
Citation	Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744
URL	https://www.wjgnet.com/1007-9327/full/v26/i15/1733.htm
DOI	https://dx.doi.org/10.3748/wjg.v26.i15.1733

Full Article (PDF)	WJG-26-1733.pdf
Full Article (Word)	WJG-26-1733.docx
Manuscript File	52516-Review.docx
Answering Reviewers	52516-Answering reviewers.pdf
Audio Core Tip	52516-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	52516-Conflict-of-interest statement.pdf
Copyright License Agreement	52516-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	52516-Language certificate.pdf
Peer-review Report	52516-Peer-review(s).pdf
Scientific Misconduct Check	52516-Scientific misconduct check.pdf
Scientific Editor Work List	52516-Scientific editor work list.pdf
CrossCheck Report	52516-CrossCheck report.pdf